Lipid Management

Two patients in their final months, on the same drug for two different reasons — one whose statin has never had an event to prevent, one whose statin is fourteen months out from a plaque that already ruptured once. The evidence behind stopping was built for the first kind of patient. Whether it reaches the second is where this case actually lives.

Four months after a stent, a patient's leg ache, an incompletely-resolving CK, and a genotype result all point at the same statin from different angles — without pointing to one clear course of action.

A single patient, two years past a heart attack, who cannot tolerate any statin. Her LDL is 92 mg/dL on ezetimibe alone — above the level at which guidelines recommend adding another drug, and below both the number and the risk category that most coverage criteria require before a payer will approve the drug most likely to bring it down.

A patient with one documented pancreatitis admission from triglycerides above 2,400 mg/dL needs an agent that lowers them fast enough to prevent a second one. The disagreement is over which matters more for choosing the first drug: a fibrate's larger acute triglyceride reduction, or an omega-3 agent's stronger cardiovascular outcomes evidence.

A florist with a family history of premature coronary death and a mildly elevated ALT/AST nobody has yet explained. US statin labeling dropped that phrase as a contraindication years ago — the question is whether her labs are what it was written to catch, or a workup still in progress.

Six weeks post-NSTEMI, LDL 92 on high-intensity statin, goal under 55. The guideline sequence says try the cheap oral pill first — the question is whether that sequence costs real risk-days in exactly the window where risk is highest.

A statin taken faithfully for years after a distant heart attack, now sitting on the medication list of a woman with advanced dementia and a prognosis measured in months. A real trial tested exactly this decision — the question is whether her own history places her inside it.

Every guideline box checked for a PCSK9 inhibitor — established ASCVD, maximal statin plus ezetimibe, LDL still above threshold — against a health plan whose structure quietly excludes the usual affordability fix. The clinical decision was never really the hard part.

Two years after a stented NSTEMI, his LDL is controlled and his triglycerides are not. The drug that addresses them was tested against a placebo that turned out not to be neutral, and the debate is about how much of that 25% still belongs to the drug.

She can't point to a test that shows anything wrong. She can point to exactly when the fog started, and it started with a prescription.

A single patient whose new hyperlipidemia diagnosis has an unusually large number of pharmacologically wrong answers before it has a right one.

A single patient whose established, effective cholesterol treatment stopped making sense the day her new immunosuppressant regimen started, and nobody has fully revisited it since.